Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis

Itô, Makoto; Kamata, Masahiro; Uchida, Hideaki; Egawa, Shota; Nagata, Mayumi; Fukaya, Saki; Hayashi, Kotaro; Fukuyasu, Atsuko; Tanaka, Takamitsu; Ishikawa, Takeko; Tada, Yayoi

doi:10.1111/bjd.21701

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Recent research demonstrated that ixekizumab rapidly improves inflammatory markers in patients with GPP. 5 GPP of pregnancy occurs most commonly in the second half to third trimester of pregnancy, which is in accordance with our case.…”

supporting

confidence: 92%

Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab

Huang

Liu

Jianjian

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

supporting

confidence: 92%

Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab

Huang

Liu

Jianjian

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…[88][89][90][91] Finally, ixekizumab was found to improve inflammatory markers in patients with GPP with systemic inflammation. 92…”

Section: Ixekizumabmentioning

confidence: 99%

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna¹,

Camela²,

Ruggiero³

et al. 2023

CCID

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a potentially life-threatening condition, characterized by recurring episodes or flares of widespread cutaneous erythema with macroscopic sterile pustules. An irregular innate immune response is linked to GPP, which is considered an auto-inflammatory disorder, while innate and adaptive immunopathogenic responses are involved in psoriasis pathogenesis. In consequence, different cytokine cascades have been suggested to be mainly involved in the pathogenesis of each different psoriasis form, with the interleukin (IL)23/IL17 axis implied in plaque psoriasis, and the IL36 pathway in the GPP. As regards GPP treatment, conventional systemic drugs available for plaque psoriasis are usually used as the first-line treatment option. However, contraindications and adverse events often limit the use of these therapies. In this scenario, biologic drugs may represent a promising treatment option. To date, even if 12 different biologics have been approved for plaque psoriasis, none of these is approved for GPP where they are employed off-label. Recently, spesolimab, an anti-IL36 receptor monoclonal antibody, has been recently approved for GPP. The purpose of this article is to assess the current literature about the use of biological therapies for the treatment of GPP to establish the basis for a shared GPP management algorithm.

show abstract

“…Ixekizumab, an interleukin (IL)-17 blockade, has demonstrated effectiveness in the treatment of genital and generalized pustular psoriasis. [ 3 ]…”

mentioning

confidence: 99%

Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis

Xia,

Liu,

Chen

et al. 2023

Indian Journal of Dermatology

View full text Add to dashboard Cite

Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis

Abstract: Abstract

Cited by 8 publications

References 11 publications

Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab

Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis

Contact Info

Product

Resources

About